Frequency and distribution of incidental findings deemed appropriate for S modifier designation on low-dose CT in a lung cancer screening program

Reiter, Michael J.; Nemesure, Allison; Madu, Ezemonye; Reagan, Lisa; Plank, April

doi:10.1016/j.lungcan.2018.03.017

Cited by 29 publications

(14 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While the primary goal of lung cancer screening is to detect early, potentially curable lung cancer in high-risk individuals, incidental detection of a variety of asymptomatic pathologies is common (14)(15)(16)(17)(18)(19)(20)(21)(22). To our knowledge, this is the first study to address reporting patterns, recommendations, and outcomes in suspected acute infectious or inflammatory lung abnormalities detected during lung cancer screening.…”

Section: Discussionmentioning

confidence: 97%

Management and Outcomes of Suspected Infectious and Inflammatory Lung Abnormalities Identified on Lung Cancer Screening CT

Mendoza

Chintanapakdee

Zhang

et al. 2021

American Journal of Roentgenology

View full text Add to dashboard Cite

The publication of this Accepted Manuscript is provided to give early visibility to the contents of the article, which will undergo additional copyediting, typesetting, and review before it is published in its final form. During the production process, errors may be discovered that could affect the content of the Accepted Manuscript. All legal disclaimers that apply to the journal pertain. The reader is cautioned to consult the definitive version of record before relying on the contents of this document.

show abstract

Section: Discussionmentioning

confidence: 97%

Management and Outcomes of Suspected Infectious and Inflammatory Lung Abnormalities Identified on Lung Cancer Screening CT

Mendoza

Chintanapakdee

Zhang

et al. 2021

American Journal of Roentgenology

View full text Add to dashboard Cite

show abstract

“…Minor and clinically insignificant incidental findings are common on LDCT and can potentially lead to unnecessary investigations, additional costs and patient anxiety. Reported prevalence of incidental findings in the thorax, as well as in adjacent neck or abdominal regions, differs widely among screening trials and a few published routine care studies, with rates from 8% to 94% [121][122][123][124][125]. The most common incidental findings occur in the cardiovascular system, followed by renal, hepatic and pulmonary lesions [122].…”

Section: Additional and Incidental Findings: Value And Managementmentioning

confidence: 99%

ESR/ERS statement paper on lung cancer screening

et al. 2020

View full text Add to dashboard Cite

In Europe, lung cancer ranks third among the most common cancers, remaining the biggest killer. Since the publication of the first European Society of Radiology and European Respiratory Society joint white paper on lung cancer screening (LCS) in 2015, many new findings have been published and discussions have increased considerably. Thus, this updated expert opinion represents a narrative, non-systematic review of the evidence from LCS trials and description of the current practice of LCS as well as aspects that have not received adequate attention until now. Reaching out to the potential participants (persons at high risk), optimal communication and shared decision-making will be key starting points. Furthermore, standards for infrastructure, pathways and quality assurance are pivotal, including promoting tobacco cessation, benefits and harms, overdiagnosis, quality, minimum radiation exposure, definition of management of positive screen results and incidental findings linked to respective actions as well as cost-effectiveness. This requires a multidisciplinary team with experts from pulmonology and radiology as well as thoracic oncologists, thoracic surgeons, pathologists, family doctors, patient representatives and others. The ESR and ERS agree that Europe's health systems need to adapt to allow citizens to benefit from organised pathways, rather than unsupervised initiatives, to allow early diagnosis of lung cancer and reduce the mortality rate. Now is the time to set up and conduct demonstration programmes focusing, among other points, on methodology, standardisation, tobacco cessation, education on healthy lifestyle, cost-effectiveness and a central registry.

show abstract

“…An examination of interradiologist concordance of "S" modifier showed 42% agreement. 26 Specific guidelines are needed to determine what is clinically significant and to improve reporting uniformity. The clinical relevance of the noncoronary significant findings is still controversial.…”

Section: Anxietymentioning

confidence: 99%

Update on Lung Cancer Screening

Brownlee

Donington

2020

Semin Respir Crit Care Med

View full text Add to dashboard Cite

Over the past 10 years, there has been substantial progress in the study and implementation of lung cancer screening using low-dose computed tomography (LDCT). The National Lung Screening Trial, the recently reported NELSON (NEderlands-Leuvens Longkanker Screenings ONderzoek) trial, and other European trials provide strong evidence for the efficacy of LDCT to reduce lung cancer mortality. This has resulted in the United State's Preventative Task Force and numerous professional medical societies adopting lung cancer screening recommendations. Despite the general acceptance of the positive effect of screening, low adoption and implementation rates remain nationally. In this article, the authors discuss the evolution and current state of the evidence for LDCT screening for lung cancer. The authors will also review the associated risks, cost, and challenges of implementation of an LDCT screening program.

show abstract

Frequency and distribution of incidental findings deemed appropriate for S modifier designation on low-dose CT in a lung cancer screening program

Cited by 29 publications

References 28 publications

Management and Outcomes of Suspected Infectious and Inflammatory Lung Abnormalities Identified on Lung Cancer Screening CT

Management and Outcomes of Suspected Infectious and Inflammatory Lung Abnormalities Identified on Lung Cancer Screening CT

ESR/ERS statement paper on lung cancer screening

Update on Lung Cancer Screening

Contact Info

Product

Resources

About